All In Biotech

Drug Trial Radar · NCT06255028

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants With Refractory B Cell-mediated Autoimmune Diseases

Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

6

Actual

Start

Feb 6, 2025

Primary completion

Aug 2028

Study completion Aug 2028

Sponsor

Lead sponsor
Century Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), idiopathic inflammatory myopathies (IIM), and diffuse cutaneous systemic sclerosis (DcSSc).

Conditions

  • Systemic Lupus Erythematosus
  • Lupus Nephritis
  • Idiopathic Inflammatory Myopathies
  • Diffuse Cutaneous Systemic Sclerosis

Interventions

  • CNTY-101Biological

    CNTY-101 cells for intravenous (IV) infusion

  • IL-2Biological

    IL-2 subcutaneous (SC) injection

  • Lymphodepleting ChemotherapyDrug

    LDC as prespecified in the protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEsTime frame: Up to 29 days
  2. Percentage of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days after first CNTY-101 infusion
  3. Recommended Phase 2 Regimen (RP2R) of CNTY-101 With/Without IL-2 (With or Without Optimized LDC)Time frame: Up to 3 months after the first CNTY-101 infusion

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Keck School of Medicine of University of Southern California

    Los Angeles, California

  • UC Davis

    Sacramento, California

  • Lurie Children's; Northwestern Medicine - Northwestern Medical Group

    Chicago, Illinois

  • Texas Children's Hospital

    Houston, Texas

  • Primary Children's Hospital

    Salt Lake City, Utah

  • Fred Hutch

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.